HPV Vaccine Available for Routine Use

On October 19, 2016, ACIP voted and the CDC approved a 2-dose vaccination regimen for Gardasil 9 for use in girls and boys aged 9-14 years. The official 2-dose HPV recommendation was published on December 16, 2016 in the MMWR. The previous 3-dose recommendation for ages 15-26 remains the same.

Gardasil 9 is available for protecting males and females against HPV:

*Gardasil 9* (9-valent HPV- 6, 11, 16, 18, 31, 33, 45, 52, 58): [Gardasil 9 VIS (PDF)]

- Licensed in 2014 and recommended for females and males by ACIP in 2015
- Recommended for immunocompromised and HIV-positive males and females aged 9-26 years, and for all males 9-21 and all females 9-26.
- Protects against oropharyngeal, anal, cervical, vaginal, vulvar, and penile precancer and cancer; and genital warts
- Contraindication: Hypersensitivity to yeast
- Schedule:
  - 2-dose series (0 and 6-12 months) for vaccination initiated at age 9-14 years;
  - 3-dose series (0, 1-2, and 6 months) for vaccination initiated at age 15-26 years, as well as immunocompromised and HIV-positive persons

### ACIP Recommendations for HPV Vaccination

<table>
<thead>
<tr>
<th>Age When Starting Series</th>
<th># of Doses</th>
<th>Schedule/Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 to 14 years</td>
<td>2</td>
<td>O, 6-12 months</td>
</tr>
<tr>
<td>15 to 26 years</td>
<td>3</td>
<td>0, 1-2, and 6 months</td>
</tr>
<tr>
<td>9 to 26 years and immunocompromised and/or HIV-positive</td>
<td>3</td>
<td>0, 1-2, and 6 months</td>
</tr>
</tbody>
</table>

**Notes:**

- Only Gardasil 9 has been distributed on CDC contracts through the VFC program since April 2016.
- ACIP recommends HPV vaccination for immunocompromised persons aged 9 through 26 years with 3 doses of HPV vaccine (0, 1-2, 6 months). Persons who should receive 3 doses are those with primary or secondary immunocompromising conditions that might reduce cell-mediated or humoral immunity, such as B lymphocyte antibody deficiencies, T lymphocyte complete or partial defects, HIV infection, malignant neoplasm, transplantation, autoimmune disease, or immunosuppressive therapy, since immune response to vaccination may be attenuated.*
- *The recommendation for a 3-dose schedule for immunocompromised persons does not apply to children with asplenia, asthma, chronic granulomatous disease, chronic liver disease, chronic lung disease, CNS anatomic barrier defects (e.g., cochlear implant), complement deficiency, diabetes, heart disease, persistent complement deficiencies, or sickle cell disease.
- There is no ACIP recommendation for routine additional 9-valent HPV vaccination of persons who previously completed a quadrivalent or bivalent vaccination series.

For people with disabilities, this document is available on request in other formats. To submit a request, please call 1-800-525-0127 (TDD/TTY call 711).